Cargando…

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

OBJECTIVE: We conducted a post hoc analysis of two randomized controlled trials, GWPCARE1 (NCT02091375) and GWPCARE2 (NCT02224703), to estimate the time to onset of cannabidiol (CBD) treatment effects (seizure reduction and adverse events [AEs]) in patients with Dravet syndrome (DS). METHODS: Patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madan Cohen, Jennifer, Checketts, Daniel, Dunayevich, Eduardo, Gunning, Boudewijn, Hyslop, Ann, Madhavan, Deepak, Villanueva, Vicente, Zolnowska, Marta, Zuberi, Sameer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456817/ https://www.ncbi.nlm.nih.gov/pubmed/34265088 http://dx.doi.org/10.1111/epi.16974

Ejemplares similares

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials
por: Li, Wenhui, et al.
Publicado: (2021)

Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)
Publicado: (2020)

Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol
por: Xu, Changqing, et al.
Publicado: (2021)

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018)

A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
por: Heger, Katrine, et al.
Publicado: (2020)

Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe
por: Cardenal‐Muñoz, Elena, et al.
Publicado: (2021)

Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype
por: Ouss, Lisa, et al.
Publicado: (2018)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
por: Devinsky, Orrin, et al.
Publicado: (2018)

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea
por: Koo, Chung Mo, et al.
Publicado: (2020)

Cannabidiol attenuates inflammatory impairment of intestinal cells expanding biomaterial-based therapeutic approaches
por: Boehm, Elisa, et al.
Publicado: (2023)

Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program
por: Pernici, Chelsea D., et al.
Publicado: (2021)

High FGF‐21 level in a cohort of 22 patients with Dravet Syndrome—Possible relationship with the disease outcomes
por: Kwong, Anna Ka‐Yee, et al.
Publicado: (2021)

Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
por: Hawkins, Nicole A., et al.
Publicado: (2021)

SCN1A Genetic Test for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy and its Clinical Subtypes) for use in the Diagnosis, Prognosis, Treatment and Management of Dravet Syndrome
por: Stenhouse, Susan A.R., et al.
Publicado: (2013)

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020)

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice
por: Patra, Pabitra Hriday, et al.
Publicado: (2020)

A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA)
por: Hahn, Cecil D., et al.
Publicado: (2022)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Cardiac arrhythmias in Dravet syndrome: an observational multicenter study
por: Shmuely, Sharon, et al.
Publicado: (2020)

Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus
por: Patel, Dipan C., et al.
Publicado: (2019)

Prevalence of Hepatitis B Virus, Genotypes, and Mutants in HBsAg-Positive Patients in Meerut, India
por: Khan, Salman, et al.
Publicado: (2019)

Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study
por: Sharma, Pravesh, et al.
Publicado: (2022)

Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome
por: Chuang, Shu-Hui, et al.
Publicado: (2021)

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models
por: Patra, Pabitra Hriday, et al.
Publicado: (2018)

Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
por: Silvinato, Antônio, et al.
Publicado: (2022)

Status of Biofilm-Forming Genes among Jordanian Nasal Carriers of Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
por: Khasawneh, Ashraf I, et al.
Publicado: (2020)

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
por: Crockett, Julie, et al.
Publicado: (2020)

Caregivers’ Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study
por: Marshall, Jade, et al.
Publicado: (2023)

Clinical profiles of patients with wheat-induced anaphylaxis at various ages of onset()
por: Du, Zhirong, et al.
Publicado: (2023)

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Genetic profiles of familial late-onset Alzheimer's disease in China: The Shanghai FLOAD study
por: Xie, Xin-Yi, et al.
Publicado: (2021)

UVB damage onset and progression 24 h post exposure in human-derived skin cells
por: Khalil, Christian, et al.
Publicado: (2017)

The gut microbiota, HPA axis, and brain in adolescent-onset depression: Probiotics as a novel treatment
por: Freimer, Daniel, et al.
Publicado: (2022)

Tailoring and evaluating the web-based ‘Partner in Balance’ intervention for family caregivers of persons with young-onset dementia
por: Bruinsma, Jeroen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u07sg4gra3n2siomnfgod58nmd